We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Diclegis (doxylamine succinate + pyridoxine hydrochloride DR tablets)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Diclegis (doxylamine succinate + pyridoxine hydrochloride DR tablets)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Diclegis is a fixed-dose combination drug product of doxylamine succinate, an antihistamine, and pyridoxine hydrochloride, a vitamin B6 analog.

    Diclegis is specifically indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

    Diclegis is supplied as a tablet for oral administration. The recommended dose is two tablets daily at bedtime. If symptoms are not adequately controlled, the dose can be increased to a maximum recommended dose of four tablets daily (one in the morning, one mid-afternoon and two at bedtime).

    Clinical Results

    FDA Approval
    The FDA approval of Diclegis was based on a double-blind, randomized, multi-center, placebo-controlled study in adult women in 7 to 14 weeks gestation (median 9 weeks of gestation) with nausea and vomiting of pregnancy. The subjects were adminitered two tablets of Diclegis or placebo at bedtime on Day 1. If symptoms of nausea and vomiting persisted into the afternoon hours of Day 2, they were directed to take the usual dose of two tablets at bedtime that night and, beginning on Day 3, to take one tablet in the morning and two tablets at bedtime. Based upon assessment of remaining symptoms at the clinic visit on Day 4, the subject may have been directed to take an additional tablet mid-afternoon. A maximum of four tablets (one in the morning, one in the mid-afternoon and two at bedtime) were taken daily. Over the treatment period, 19% of Diclegis-treated subjects remained on 2 tablets daily, 21% received 3 tablets daily, and 60% received 4 tablets daily. The primary efficacy endpoint was the change from baseline at Day 15 in the Pregnancy Unique-Quantification of Emesis (PUQE) score. This score incorporates the number of daily vomiting episodes, number of daily heaves, and length of daily nausea in hours, for an overall score of symptoms rated from 3 (no symptoms) to 15 (most severe). At baseline, the mean PUQE score was 9.0 in the Diclegis arm and 8.8 in the placebo arm. There was a 0.7 (p-value 0.006) mean decrease (improvement in nausea and vomiting symptoms) from baseline in PUQE score at Day 15 with Diclegis compared to placebo.

    Side Effects

    The most common adverse reaction associated with the use of Diclegis is somnolence.

    Mechanism of Action

    Diclegis is a fixed-dose combination drug product of doxylamine succinate, an antihistamine, and pyridoxine hydrochloride, a vitamin B6 analog. The mechanism of action by which Diclegis exerts its’ effects is unknown.

    Literature References

    Koren, G The return to the USA of doxylamine-pyridoxine delayed release combination (Diclegis) for morning sickness--a new morning for American women. Journal of population therapeutics and clinical pharmacology 2013;20(2):e161-2

    Additional Information

    For additional information regarding Diclegis or nausea and vomiting of pregnancy, please visit the Diclegis web page.

    Approval Date: 2013-04-01
    Date Created: 2013-10-11 12:00:00
    Company Name: Duchesnay USA
    Back to Listings

    Upcoming Events

    • 09Dec

      The Age of eSource: Modernizing Clinical Trials

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Patient-phsyician-consultation

      Giving Patients Back Their Voice in Clinical Trials

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing